Phase IIa Double-Blind, Placebo- Controlled, Randomized, Efficacy and Safety Study of Subcutaneously Administered HER-096 in Patients with Early-Stage Parkinson’s Disease HERMOD

Project Information

HERMOD

Grant agreement ID: 101286586

DOI

10.3030/101286586

EC signature date 8 July 2026

Start date 1 June 2026

End date 31 May 2030

Funded under

• Health

Total cost

€ 7 992 761,25

EU contribution

€ 7 992 761,25

Coordinated by

REGION STOCKHOLM
Sweden

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (1)

HER-096 is a CDNF-derived brain-penetrating peptidomimetic that protects dopaminergic neurons in a mouse synucleinopathy model of Parkinson’s disease

Author(s): Natalia Kulesskaya, Arnab Bhattacharjee, Kira M. Holmström, Päivi Vuorio, Alexandre Henriques, Noëlle Callizot, Henri J. Huttunen
Published in: Cell Chemical Biology, Issue 31, 2024, ISSN 2451-9456
Publisher: Elsevier BV
DOI: 10.1016/J.CHEMBIOL.2023.11.005